Ocular Therapeutix

OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

24 Mar 25

Updated

14 Dec 25

Views

159

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

47.8%

7D

-13.7%

Loading

1Y

47.8%

7D

-13.7%

You can edit this narrative until Dec 15 12:10 AM. Then, changes will post as Updates.

Author's Valuation

US$24.1748.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 14 Dec 25

Fair value Increased 5.45%

OCUL: Derisked Diabetic Retinopathy Pivotal Program Will Drive Future Upside Potential

Analysts raised their price target on Ocular Therapeutix by approximately $1.25 per share, citing derisking of the pivotal Nonproliferative Diabetic Retinopathy program and the potential for blockbuster revenue growth, along with upcoming wet AMD pivotal readouts that are expected to drive meaningful near term value creation. Analyst Commentary Bullish analysts view the updated price target as a reflection of increased confidence in Ocular Therapeutix's execution against its late stage ophthalmology pipeline, particularly in Nonproliferative Diabetic Retinopathy and wet AMD.

Shared on 29 Nov 25

OCUL: Pivotal Retinopathy Trial Progress Will Drive Substantial Upside Potential

Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing new developments in a derisked pivotal program for Nonproliferative Diabetic Retinopathy as well as potential near-term value from upcoming wet AMD trial readouts. Analyst Commentary Following the recent price target increase for Ocular Therapeutix, analysts have provided a range of perspectives on the company's opportunities and risks.

Shared on 15 Nov 25

Fair value Increased 4.56%

OCUL: Pivotal Trial Progress in Diabetic Retinopathy Will Drive Long-Term Upside

Analysts have increased their price target for Ocular Therapeutix by $1.00 to $22.92, citing recently derisked pivotal programs that enhance the company's potential for both near-term and long-term value creation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the recent price target increase as evidence of growing confidence in the company's clinical programs and strategic direction.

Shared on 01 Nov 25

Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing the newly derisked pivotal program in Nonproliferative Diabetic Retinopathy and anticipated value from upcoming wet AMD trial results as justification for their greater optimism. Analyst Commentary Recent analyst discussions have centered on the positive momentum surrounding Ocular Therapeutix due to its progress in developing treatments for retinal diseases.

Shared on 17 Oct 25

Fair value Increased 8.68%

Ocular Therapeutix saw its analyst price target increase significantly from $20 to $29, as analysts cite newly available de-risked data in Nonproliferative Diabetic Retinopathy and upcoming pivotal readouts in wet AMD as key drivers of enhanced valuation. Analyst Commentary Following the recent price target revision, analysts have weighed in with both optimistic and cautious perspectives regarding Ocular Therapeutix's outlook.

Shared on 03 Oct 25

Fair value Increased 16%

Analysts have raised their fair value estimate for Ocular Therapeutix from $17.45 to $20.17 per share, citing increased clarity around the company's pivotal program in Nonproliferative Diabetic Retinopathy and its emerging opportunities in wet AMD. Analyst Commentary Analysts have provided detailed insights following recent developments at Ocular Therapeutix, offering a balanced perspective on both the opportunities and challenges influencing the company's valuation and future growth prospects.

Shared on 01 May 25

Fair value Increased 6.82%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 9.02%

AnalystConsensusTarget has decreased revenue growth from 43.3% to 29.3%, increased future PE multiple from 100.5x to 127.6x and increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on 26 Mar 25

Fair value Increased 2.87%

AnalystConsensusTarget Fair Value

US$24.17

48.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

52.38%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$46.70m

Earnings '28

x

164.64x

PE Ratio '28

=

US$7.69b

Market Cap '28

US$7.69b

Market Cap '28

/

260.99m

No. shares '28

=

US$29.46

Share Price '28

US$29.46 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$24.07

Fair Value '25